PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

The lead­ing an­ti-tau an­ti­body has failed its first Phase II test­ing, cast­ing a shad­ow on a pop­u­lar tar­get (just trail­ing amy­loid be­ta) for Alzheimer’s dis­ease.

Roche and AC Im­mune are quick to ac­knowl­edge dis­ap­point­ment in the topline read­out, which sug­gest­ed that se­morinemab did not re­duce cog­ni­tive de­cline among pa­tients with ear­ly Alzheimer’s dis­ease, who are ei­ther just start­ing to have symp­toms or have mild man­i­fes­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.